Published in J Med Econ on July 16, 2012
SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives. Vasc Health Risk Manag (2016) 0.79
Exenatide extended-release; clinical trials, patient preference, and economic considerations. Patient Prefer Adherence (2013) 0.78
Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives. Ther Clin Risk Manag (2015) 0.77
Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes. Diabetes Metab Syndr Obes (2014) 0.75
Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetes. Adv Ther (2014) 0.75
How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review. Pharmacoeconomics (2016) 0.75
Factors influencing elevated ethanol consumption in adolescent relative to adult rats. Alcohol Clin Exp Res (2005) 2.43
Anxiogenic effects during withdrawal from acute ethanol in adolescent and adult rats. Pharmacol Biochem Behav (2003) 1.81
Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. Value Health (2013) 1.77
Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β-agonists. Appl Health Econ Health Policy (2014) 1.51
The current and future burden and cost of overactive bladder in five European countries. Eur Urol (2006) 1.06
Excess morbidity and cost of failure to achieve targets for blood pressure control in Europe. Blood Press (2002) 1.03
The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine. Vaccine (2003) 1.01
Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis. J Med Econ (2012) 0.94
Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK. J Med Econ (2011) 0.89
Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD. Respir Med (2011) 0.89
Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Postgrad Med (2012) 0.88
ER:YAG laser for 3-dimensional debridement of canal systems: use of photon-induced photoacoustic streaming. Dent Today (2012) 0.87
Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective. Curr Med Res Opin (2010) 0.84
Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals. Cardiovasc Diabetol (2013) 0.84
Major bleeding rates after prophylaxis against venous thromboembolism: systematic review, meta-analysis, and cost implications. Int J Technol Assess Health Care (2004) 0.82
Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs. Curr Med Res Opin (2010) 0.82
Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide. Endocr Pract (2012) 0.81
The 'Healthy Dads, Healthy Kids' community effectiveness trial: study protocol of a community-based healthy lifestyle program for fathers and their children. BMC Public Health (2011) 0.81
The economic value of reducing medication dosing frequency with drug delivery technologies: an evidence assessment. J Med Econ (2010) 0.80
Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine. Ann Pharmacother (2014) 0.80
Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States. J Med Econ (2012) 0.79
Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly. J Diabetes (2014) 0.78
Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications. Postgrad Med (2012) 0.78
Electroglottographic analysis of actresses and nonactresses' voices in different levels of intensity. J Voice (2013) 0.76
An economic evaluation of adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study. Curr Med Res Opin (2004) 0.76
Development and validation of the self-management profile for type 2 diabetes (SMP-T2D). Health Qual Life Outcomes (2012) 0.75
An economic evaluation of the costs and benefits of heparin rationalisation in a hospital pharmacy. Pharm World Sci (2004) 0.75
Laryngoscopic, acoustic, perceptual, and functional assessment of voice in rock singers. Folia Phoniatr Logop (2014) 0.75
Intracerebral hemorrhage following multiple bee stings. JAAPA (2013) 0.75
Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control. Postgrad Med (2013) 0.75
Costs of chemotherapy for indolent follicular non-Hodgkin's lymphoma in the UK: an observational study. Acta Haematol (2006) 0.75